Crossmark

Off-label use of anlotinib in malignancies’ treatment: efficacy and management of adverse reactions

Published Online: 2025-02-03

Published Print: 2025-04

Authors

Wang, Guangli

Wang, Yuling

Jin, Changhao

Sun, Xiaodan https://orcid.org/0000-0002-5119-383X
Funding

Funding for this research was provided by:

Jilin Province Science and Technology Development Program Project (YDZJ202501ZYTS183)

the Project of Lung Cancer Targeted Therapy Research of Beijing CSCO (No. Y-2021AST/qn-0013)
License Information

Text and Data Mining valid from 2025-02-03

Version of Record valid from 2025-02-03
More Information

Article History

Received: 3 August 2024

Revised: 15 January 2025

Accepted: 16 January 2025

First Online: 3 February 2025

Declarations

:

: The authors declare no competing interests.

Document is current